GSK plc to acquire RAPT Therapeutics Inc. for $58.00 per share, with an estimated upfront investment of $1.9 billion.

GSK entered into a definitive agreement to acquire RAPT Therapeutics, including RAPT’s long-acting anti-immunoglobulin E (IgE ...

South Korean biotech Alteogen (Kosdaq: 196170) has signed an exclusive license agreement with Tesaro, a unit of GSK (LSE: GSK ...

GSK has agreed to pay $58 per RAPT share, with an upfront payment of $1.9 billion, that will give it global rights to ...

GSK has agreed to acquire RAPT Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing novel ...

GSK's RAPT Therapeutics acquisition will strengthen the former's immunology pipeline – specifically its offerings for food ...

Viking has identified Neil Aubuchon as the person to oversee its commercial preparations. Aubuchon has joined the biotech as ...

GSK touted recent deals as source of fresh revenues amid patent expiries and an AI-driven boost to drug discovery.

UK pharma major GSK today announced positive results from its two pivotal Phase III trials, B-Well 1 [NCT05630807] and B-Well ...

US-based biotech firm is developing treatment for allergies such as nuts, milk and eggs in children and adults ...